Drug Profile
EQ 101
Alternative Names: BNZ-1; BNZ132-1; BNZ132-1-40; EQ-101Latest Information Update: 25 Dec 2023
Price :
$50
*
At a glance
- Originator Bioniz
- Developer Bioniz; Equillium
- Class Antineoplastics; Antivirals; Peptides; Skin disorder therapies
- Mechanism of Action Interleukin 15 inhibitors; Interleukin 15 receptor antagonists; Interleukin 2 inhibitors; Interleukin 2 receptor antagonists; Interleukin 9 inhibitors; Interleukin 9 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Cutaneous T-cell lymphoma
- Phase II Alopecia areata; Large granular lymphocytic leukaemia; T-cell leukaemia
- Research Vitiligo
- No development reported Adult T-cell leukaemia-lymphoma; Tropical spastic paraparesis
Most Recent Events
- 21 Dec 2023 Adverse events data from a phase II trial in Alopecia areata released by Equillium
- 08 Nov 2023 Equillium completes enrolment in the phase II trial for Alopecia areata in Australia and New Zealand (IV)
- 31 Mar 2023 Bioniz has patent protection for EQ 101 in USA, Australia, Canada, Japan, Brazil, China and Europe and has patents pending in US, Brazil, Australia, Canada, China, Europe, Hong Kong, South Korea and Japan